Enveric Biosciences (ENVB) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enveric Biosciences is the larger company by market cap ($6.0 million vs $5.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENVB | TPST |
|---|---|---|
| Share price | $1.35 | $0.287 |
| Market cap | $6.04M | $5.74M |
| 1-day change | -4.26% | -6.18% |
| YTD return | — | -90.00% |
| 1-year return | — | -91.80% |
| 5-year return | — | -99.77% |
| EPS (TTM) | $-13.01 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.77M | $-26.26M |
| 52-week high | $13.25 | $4.22 |
| 52-week low | $1.17 | $0.28 |
| Distance from 52-week high | -89.81% | -93.20% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +2339.02% |
| Average volume | 56.55K | 2.56M |
| Shares outstanding | 4.48M | 20.00M |
| Employees | 5 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ENVB vs TPST FAQ
Which is bigger, Enveric Biosciences or Tempest Therapeutics?
Enveric Biosciences (ENVB) is larger, with a market capitalization of $6.04M compared with $5.74M for Tempest Therapeutics (TPST).
Are Enveric Biosciences and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.